{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:14Z","timestamp":1794666134215,"version":"4.9.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Clozapine is the preferred medication for treatment-resistant schizophrenia with therapeutic drug monitoring (TDM) suggested to mediate its safe and effective use. However, clozapine TDM is not a ubiquitous element of care in clinical practice. Understanding the current state of clinicians' perceptions of and barriers to clozapine TDM is a crucial step in improving its use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A survey related to the use, perceptions, and barriers of clozapine TDM was distributed across multiple national organizations in the United States, representing several disciplines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Most of the 190 respondents were consultants or attending physicians (42.5%) or pharmacists (52.3%). Nearly 80% of respondents had ordered clozapine level measurements in the year before completing the survey but identified slow turnaround time (TaT) as an important barrier; 73.5% of respondents noted that level measurements were performed at an offsite laboratory. Although 86.8% agreed that clozapine levels should be checked once an initial target dose was reached, less than half would subsequently order clozapine level measurements routinely, unless clinical factors such as nonadherence (96.5% agreement), new interaction (94.5% agreement), or change in smoking status (94.5% agreement) occurred. More pharmacists than prescribers indicated confidence in interpreting and clinically applying clozapine TDM results (84.6% versus 70.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.024), with a similar finding between the groups regarding faster clozapine TDM TaT, resulting in improved patient safety (89.0% versus 68.7% agreement,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). In addition, more pharmacists would also conduct clozapine TDM in the setting of an acute inflammatory or infectious process (84.9% versus 61.2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These data provide insights into clozapine TDM perception, availability, TaT, and barriers. Further research is required to assess whether a faster TaT and more frequent clozapine TDM positively influence patient outcomes from a safety and effectiveness perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001415","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:01:15Z","timestamp":1765429275000},"page":"512-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Perceptions, Use, and Barriers of Clozapine Therapeutic Drug Monitoring in the United States: A Multidisciplinary Survey Study"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9375","authenticated-orcid":false,"given":"Jonathan G.","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Gatzlaff","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Santa Barbara Cottage Hospital\u2014Santa Barbara, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Leloux","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn N.","family":"Bye","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gannon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania;"},{"name":"Comprehensive Recovery Services, Western Psychiatric Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. N. Roy","family":"Chengappa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania;"},{"name":"Comprehensive Recovery Services, Western Psychiatric Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[{"name":"Hospital of Psychiatry Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich, Zurich, Switzerland;"},{"name":"The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York;"},{"name":"Zucker School of Medicine, Hofstra\/Northwell, Hempstead, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matej","family":"Markota","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert O.","family":"Cotes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota;"},{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"R1-20261114","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophr Res"},{"key":"R3-20261114","first-page":"165","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","volume":"268","author":"De Las Cuevas","year":"2024","journal-title":"Schizophr Res"},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/schbul\/sby052","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years","volume":"45","author":"Vermeulen","year":"2019","journal-title":"Schizophr Bull"},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am J Psychiatry"},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","article-title":"Clozapine treatment for suicidality in schizophrenia: International suicide prevention Trial (InterSePT)","volume":"60","author":"Meltzer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2023.08.029","article-title":"Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey","volume":"268","author":"G\u00fcrcan","year":"2024","journal-title":"Schizophr Res"},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus Guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An International Adult Guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"de Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/schbul\/sbad030","article-title":"Clozapine Optimization: a Delphi Consensus Guideline from the treatment response and resistance in psychosis working Group","volume":"49","author":"Wagner","year":"2023","journal-title":"Schizophr Bull"},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FTD.0000000000001233","article-title":"Making clozapine therapeutic drug monitoring essential for optimal patient care","volume":"46","author":"Leung","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/FTD.0000000000001188","article-title":"A short turnaround of clozapine blood level results within 6 hours is essential for effective management of severely ill persons with treatment-resistant schizophrenia","volume":"46","author":"Vincent","year":"2024","journal-title":"Ther Drug Monit"},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.2147\/NDT.S163839","article-title":"Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations","volume":"14","author":"Mayerova","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"9872936","DOI":"10.1155\/2020\/9872936","article-title":"Population pharmacokinetics of clozapine: a systematic review","volume":"2020","author":"Albitar","year":"2020","journal-title":"Biomed Res Int"},{"key":"R16-20261114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1192\/bjp.2023.27","article-title":"Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis","volume":"222","author":"Northwood","year":"2023","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s10597-021-00847-0","article-title":"A comparison of attitudes, comfort, and knowledge of clozapine among two diverse samples of US psychiatrists","volume":"58","author":"Cotes","year":"2022","journal-title":"Community Ment Health J"},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/JCP.0000000000001982","article-title":"Improving result turnaround time as a crucial factor to","volume":"45","author":"Bye","year":"2025","journal-title":"J Clin Psychopharmacol"},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/15622975.2024.2367138","article-title":"The European psychiatric association (EPA) - early career psychiatrists committee survey on trainees' and early-career psychiatrists' attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment","volume":"25","author":"Schoretsanitis","year":"2024","journal-title":"World J Biol Psychiatry"},{"key":"R20-20261114","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2045125315588032","article-title":"Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use","volume":"5","author":"Law","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"key":"R21-20261114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bdi.12714","article-title":"Delphi survey of maintenance lithium treatment in older adults with bipolar disorder: an ISBD task force report","volume":"21","author":"Shulman","year":"2019","journal-title":"Bipolar Disord"},{"key":"R22-20261114","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881103017002003","article-title":"Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology","volume":"17","author":"Goodwin","year":"2003","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"R23-20261114","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/15622970902823202","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania","volume":"10","author":"Grunze","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"R24-20261114","article-title":"Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panel","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"R25-20261114","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0269881121991567","article-title":"Point-of-care measurement of clozapine concentration using a finger-stick blood sample","volume":"35","author":"Taylor","year":"2021","journal-title":"J Psychopharmacol"},{"key":"R26-20261114","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/FTD.0000000000000777","article-title":"Comparison of novel Immunoassay with liquid Chromatography\/Tandem mass spectrometry (LC-MS\/MS) for therapeutic drug monitoring of clozapine","volume":"42","author":"Buckley","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R27-20261114","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1373\/jalm.2017.023341","article-title":"Executive summary: American Association of Clinical Chemistry Laboratory medicine practice guideline-using Clinical Laboratory tests to monitor drug therapy in pain management patients","volume":"2","author":"Jannetto","year":"2018","journal-title":"J Appl Lab Med"},{"key":"R28-20261114","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/00365513.2022.2056858","article-title":"Challenged comparison of tacrolimus assays","volume":"82","author":"Cremers","year":"2022","journal-title":"Scand J Clin Lab Invest"},{"key":"R29-20261114","first-page":"53","article-title":"Comfort level and barriers to the appropriate use of Clozapine: a Preliminary Survey of US psychiatric residents","volume":"44","author":"Singh","year":"2020","journal-title":"Acad Psychiatry J Am Assoc Directors Psychiatr Residency Train Assoc Acad Psychiatry"},{"key":"R30-20261114","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2004-832687","article-title":"The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry","volume":"37","author":"Baumann","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"R31-20261114","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1472-8206.2010.00815.x","article-title":"French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs","volume":"24","author":"Rougemont","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"R32-20261114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-977712","article-title":"Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medico-scientific evidence","volume":"40","author":"Ulrich","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"R33-20261114","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophr Res"},{"key":"R34-20261114","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1176\/appi.ajp.20230744","article-title":"High burden of ileus and Pneumonia in clozapine-treated individuals with schizophrenia: a Finnish 25-Year Follow-Up register Study","volume":"181","author":"Partanen","year":"2024","journal-title":"Am J Psychiatry"},{"key":"R35-20261114","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1176\/appi.ajp.20240778","article-title":"Clozapine's high incidence of ileus and pneumonia demand better clinical strategies-how do we get there?","volume":"181","author":"Chengappa","year":"2024","journal-title":"Am J Psychiatry"},{"key":"R36-20261114","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/acps.13801","article-title":"Correlation between clozapine and CRP levels in relation to smoking status","volume":"152","author":"Smith","year":"2025","journal-title":"Acta Psychiatr Scand"},{"key":"R37-20261114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4088\/JCP.v69n0509","article-title":"Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases","volume":"69","author":"Palmer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"R38-20261114","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.japh.2022.05.013","article-title":"Iatrogenic clozapine intoxication after hospital admission: A case-based rationale for an inpatient pharmacy clozapine monitoring service","volume":"62","author":"Leung","year":"2022","journal-title":"J Am Pharm Assoc"},{"key":"R39-20261114","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.rpsm.2022.06.001","article-title":"A Covid-19 outbreak in a Spanish long-term psychiatric hospital led to infections in 6 clozapine patients: elevations in their plasma clozapine levels","volume":"15","author":"Arrojo-Romero","year":"2022","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"R40-20261114","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/IJPSYM.IJPSYM_379_19","article-title":"Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview","volume":"42","author":"de Leon","year":"2020","journal-title":"Indian J Psychol Med"},{"key":"R41-20261114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bcp.15691","article-title":"A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status","volume":"90","author":"Reeves","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R42-20261114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/JCP.0000000000001653","article-title":"Clozapine: dose, sex, ethnicity, smoking habit, age, body weight, and plasma clozapine and N -Desmethylclozapine (Norclozapine) concentrations in clinical practice","volume":"43","author":"Flanagan","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"R43-20261114","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0000000000001018","article-title":"Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review","volume":"39","author":"Ruan","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R44-20261114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/FTD.0000000000001156","article-title":"Therapeutic drug level monitoring of antipsychotics at an inpatient psychiatric Hospital","volume":"46","author":"Bhavsar","year":"2024","journal-title":"Ther Drug Monit"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:19Z","timestamp":1794664819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001415","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2025-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}